A
Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient: 1. Obtains access to the information in a personal capacity; 2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services; 3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body; 4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Message :
Required fields
NEW YORK, May 19, 2021 /PRNewswire/ Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system (CNS) disorders and rare diseases, announced today that it has commenced an underwritten public offering of shares of common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering. In addition, the Company intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the aggregate number of shares of common stock sold in the offering on the same terms and conditions. All of the shares of common stock in the offering will be sold by Seelos.
Aker ASA: Cognite Announces USD 150 Million Investment by TCV
OSLO, Norway, May 19, 2021 /PRNewswire/
Aker ASA ( Aker ) today announced that Cognite has raised USD 150 million in a Series B investment by TCV, a leading technology-focused growth equity firm. The new funding round will allow Cognite to accelerate growth initiatives, including product development and international expansion. The investment round values Cognite at USD 1.6 billion, marking one of the largest private founding rounds for a Software-as-a-Service (SaaS) company in Europe.
The Series B investment round comes as Cognite continues to experience significant customer growth and is scaling globally. Cognite s flagship product, the software platform Cognite Data Fusion (CDF), helps industries with digital transformation by liberating, safeguarding, and translating data from sensors, systems, and other sources into one common language. The data contextualized by CDF empowers companies to drive industrial applic
Seelos Therapeutics Announces Proposed Public Offering of Common Stock
News provided by
Share this article
Share this article
NEW YORK, May 19, 2021 /PRNewswire/ Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system (CNS) disorders and rare diseases, announced today that it has commenced an underwritten public offering of shares of common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering. In addition, the Company intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the aggregate number of shares of common stock sold in the offering on the same terms and conditions. All of the shares of common stock in the offering will be sold by Seelos.
Ferguson PLC Announces Results for the Three Months Ended April 30, 2021 finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.